REPAIR Technologies

Repair Biotechnologies is a preclinical-stage biotechnology company focused on developing therapies that target the root causes of age-related diseases and metabolic disorders. The company's primary focus is its Cholesterol Degrading Platform (CDP), which utilizes a proprietary bacterial enzyme delivered via mRNA-LNP technology to break down excess intracellular cholesterol, aiming to treat atherosclerosis and familial hypercholesterolemia. Additionally, the company is developing a thymic regeneration therapy designed to restore immune function by reversing thymic atrophy. By addressing cellular damage and organ decline directly, Repair Biotechnologies aims to extend healthy human lifespan and treat chronic conditions that currently lack curative options.